|
|||||
|
|
Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label,long-term extension study (ORAL Sequel) |
|
| Authors: | Mueller Ruediger B Schulze-Koops Hendrik Furst Daniel E Cohen Stanley B Kwok Kenneth Wang Lisy Killeen Tim von Kempis Johannes |
| Institution: | 1.Rheumazentrum Ostschweiz, St. Jakobsstr. 20, 9000, St. Gallen, Switzerland ;2.Division of Rheumatology and Immunology, Kantonsspital St. Gallen, St. Gallen, Switzerland ;3.Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians-University Munich, Munich, Germany ;4.UCLA, Los Angeles, CA, USA ;5.University of Washington, Seattle, WA, USA ;6.University of Florence, Florence, Italy ;7.Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, USA ;8.Pfizer Inc, New York, NY, USA ;9.Pfizer Inc, Groton, CT, USA ;10.Pfizer AG, Zürich, Switzerland ; |
| Abstract: | Clinical Rheumatology - We assess the impact of switching versus staying on the same tofacitinib dose on efficacy and safety in patients with rheumatoid arthritis (RA). ORAL Sequel was an... |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |